RECOGNIZED FOR ITS INTERNAL COMMUNICATIONS PLAN FOR SAWAIStevie® Award Presentation to Upsher-Smith Left to right: Daina Basile (Kovak-Likly Communications), Elizabeth Likly (Kovak-LiklyCommunications), Jennifer Colvin (Upsher-Smith), Carol Weeklund (Upsher-Smith)
PHARMACEUTICALS’ACQUISITION OF UPSHER-SMITH LABORATORIES
Maple Grove, MN – June ... Read More
Osaka, Japan – June 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the transfer of manufacturing and marketing approval of Zomig® Tablets ... Read More
Osaka, Japan –June 14, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of seven compounds with 17 strengths of generic drugs. Sawai’s product line now ... Read More
Osaka, Japan –June 6, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI]*.
This approval expands the indication of OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI] to include the ... Read More
Products have Combined Annual Sales of More than $1.6 Billion
Maple Grove, MN – June 1, 2018 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has entered into an exclusive agreement with a pharmaceutical partner to ... Read More
Maple Grove, MN – May 1, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the ... Read More
Eligible Patients Pay $0 Per Prescription for Qudexy®
Maple Grove, MN – April 18, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be featuring Platinum Pass, the latest addition to the Access Pathways® ... Read More
Osaka, Japan –April 4, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of two partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OLANZAPINE Tablets 2.5mg “SAWAI”, 5mg “SAWAI”, 10mg “SAWAI” and Fine Granules 1% “SAWAI” ... Read More
Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018.
OrganizationalChanges
“Development QA” is renamed “QA Department”.
※The ... Read More
